Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044364 | 0.84 | HSD11B1 (0.77) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL6236172 | 0.84 | HSD11B1 (1.00) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL27943800 | 0.83 | HSD11B1 (0.74) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL9870334 | 0.83 | HSD11B1 (0.65) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL6212608 | 0.83 | HSD11B1 (0.74) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL5493454 | 0.80 | HSD11B1 (0.75) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL662218 | 0.79 | HSD11B1 (0.64) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL662115 | 0.79 | HSD11B1 (0.68) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL31164032 | 0.79 | HSD11B1 (0.68) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL5492171 | 0.79 | HSD11B1 (0.69) | HSD11B1POLBMGLLKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | HSD11B1 1/4885POLB 1926/4885MGLL 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.